Trial Profile
A Phase II Study of NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab (NEOADAPT)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Anastrozole; Exemestane; Letrozole; Leuprorelin
- Indications Adenocarcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms NEOADAPT
- 17 Jan 2020 Status changed from active, no longer recruiting to discontinued.
- 14 Dec 2019 Results presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 27 Sep 2018 Planned End Date changed from 1 Jul 2018 to 1 Dec 2018.